Antibiotic, Zerbaxa, receives FDA approval for treating hospital-acquired pneumonia

The U.S. Food and Drug Administration today approved a new indication for the previously FDA-approved drug, Zerbaxa (ceftolozane and tazobactam) for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in patients 18 years and older. The FDA initially approved Zerbaxa in 2014 to treat complicated intra-abdominal infections and for complicated urinary tract infections. "A ["]

The post Antibiotic, Zerbaxa, receives FDA approval for treating hospital-acquired pneumonia appeared first on Outbreak News Today.